Compumedics secures significant sale in Germany

Compumedics Limited (ASX: $CMP) has secured another significant order for its world-leading Okti neurological amplifier, with a sale worth $1m (EUR0.6m) to two significant epilepsy hospitals in Berlin. The ongoing strong sales performance is being underpinned by the new Compumedics Okti® neurological wireless amplifier, with FY24 sales orders taken in Europe 63% higher than the previous year at $7.6m over FY23 at $4.6m.

Executive Commentary on Compumedics' Sales Performance

The ongoing strong sales performance in Europe, particularly in Germany and France, demonstrates the growing demand for our innovative Okti neurological amplifier. This significant sale to two leading epilepsy hospitals in Berlin further solidifies our position as a key player in the neurological diagnostic and monitoring devices market. The European market for Compumedics is estimated to be as high as EUR300m PA with 10% growth, and we are well-positioned to capitalize on this growth potential.

Summary of Compumedics' Sales Performance and Outlook

Compumedics' latest sale of the Okti neurological amplifier to two prominent epilepsy hospitals in Berlin reflects the company's continued success in the European market. With a strong FY24 performance and a 63% increase in sales orders in Europe, Compumedics is poised for further growth. The European market for Compumedics is estimated to be up to EUR300m PA with 10% growth, indicating significant opportunities for the company. The innovative Okti amplifier, with its premium signal quality and comprehensive features, has been well-received by major sites in Europe, positioning Compumedics for continued success in the neurological diagnostic and monitoring devices sector.